The Work We Fund

Funded projects
1,200+
Men's Health Partners
20
Countries
20
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Movember – Distinguished Gentleman’s Ride Clinician Scientist Award - 2017

Movember Funding to Date

-

What we seek to achieve

Clinician Scientist Awards aim to support outstanding, clinically qualified professionals who have gained a PhD in health research, to combine their clinical career with a research career and establish themselves as independent researchers in the field of prostate cancer.

Country
Australia
Co-funded
Distinguished Gentleman's Ride - AUD 351,669
Implemented by
Movember Foundation
Project start date
Jan 2018
Project Status
In Progress

About the project

The appropriate selection of men with early prostate cancer for radical treatments is complicated by our inability to accurately predict the impact a particular cancer may have on a patient’s future wellbeing. In addition, for men with advanced cancer, the response to standard hormonal therapy is suboptimal. Using patient-derived samples Dr Corcoran will investigate new ways to predict disease outcome as well as investigate mechanisms whereby prostate cancers become resistant to hormonal agents.

Key elements of the study:

•    Determine the patterns and drivers of metastases in patients with lethal   
        prostate cancer
•    Investigate the potential of a circulated tumour DNA-based ‘metastatic 
        signal’ in risk stratification at the time of diagnosis
•    Identify determinants of response to second generation anti-androgens
•    Improve tumour response to neo-adjuvant anti-androgen therapy

The study will inform the development of a blood or plasma based test for risk stratification at the time of early diagnosis; will establish whether castration-resistance is hardwired in prostate cancers, and whether it has a molecular signature that can be used to predict likely response prior to treatment; It also has the potential to reveal new mechanisms of resistance that can be targeted for therapeutic effect. Furthermore, the results have the potential to dramatically improve the therapeutic response to ADT and impact clinical outcomes.
 
This application underwent a peer review process involving a panel of experts in clinical and translational research across the prostate cancer field.

>
Page 1 of 22